alovudine and axitinib
alovudine has been researched along with axitinib in 4 studies
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bejot, R; Bhakoo, KK; Goggi, JL; Moonshi, SS | 1 |
| Algazi, AP; Bastian, BC; Behr, S; Cha, E; Chong, K; Coakley, F; Cortez, B; Daud, AI; Hwang, J; Liu, S; McCalmont, T; Ortiz-Urda, SM; Pampaloni, MH; Quiroz, A | 1 |
| Bruce, JY; Carmichael, LL; Eickhoff, JC; Heideman, JL; Jeraj, R; Kolesar, JM; Liu, G; Perlman, SB; Scully, PC | 1 |
| Bruce, JY; Carmichael, L; Eickhoff, J; Jeraj, R; Kolesar, J; Liu, G; Perlman, S; Scarpelli, M | 1 |
Trials
2 trial(s) available for alovudine and axitinib
| Article | Year |
|---|---|
The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carboplatin; Dideoxynucleosides; Female; Humans; Imidazoles; Indazoles; Male; Melanoma; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Radiography; Treatment Outcome | 2015 |
Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography.
Topics: Adult; Aged; Axitinib; Dideoxynucleosides; Disease Progression; Female; Fluorine Radioisotopes; Humans; Imidazoles; Indazoles; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals; Substance Withdrawal Syndrome; Tomography, X-Ray Computed; Vascular Endothelial Growth Factor A | 2015 |
Other Studies
2 other study(ies) available for alovudine and axitinib
| Article | Year |
|---|---|
Stratification of 18F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors.
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Cell Line, Tumor; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Imidazoles; Indazoles; Isotope Labeling; Mice; Neoplasms, Experimental; Peptides, Cyclic; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2013 |
Topics: Adult; Aged; Aged, 80 and over; Axitinib; Dideoxynucleosides; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor A | 2016 |